Prognostic Factors for Survival in Patients with Metastatic Renal Cancer Treated with Biological Response Modifiers

Sridhar Mani, Mary B. Todd, Karol Katz, Wen Jen Poo

Research output: Contribution to journalArticle

126 Citations (Scopus)

Abstract

Purpose: Clinical characteristics prognostic of survival in patients with metastatic renal cell carcinoma treated with biological response modifiers are poorly understood. Understanding these prognostic features may help with better stratification of patients in clinical trials and define further appropriate treatment for each prognostic subgroup. Materials and Methods: A retrospective study of 84 patients with recurrent or metastatic renal cancer was conducted to identify prognostic factors for survival in patients who received biological response modifiers (alpha-interferon, beta-interferon, gamma-interferon and interleukin-2). Results: Univariate analysis identified Eastern Cooperative Oncology Group (ECOG) performance status (1 versus 0, p less than 0.001), bone metastasis (p = 0.008), recent weight loss (greater than 10 percent of total body weight versus no loss, p = 0.028), history of nephrectomy (no versus yes, p = 0.025), recurrence at the renal bed (p = 0.043) and sarcomatoid histology (yes versus no, p less than 0.001) as important prognostic indicators. Multivariate analysis of prognostic factors in this patient population indicated that ECOG performance status, sarcomatoid histology and bone metastasis were most significant, while other factors were less significant (p greater than 0.05) after adjusting for ECOG performance status and sarcomatoid histology. Based on the total positive number of 5 risk factors defined previously the study population separates into 3 risk groups, with a median survival from the low to high risk groups of 14.4, 10.9 and 1.3 months, respectively. Prognostic scores based only on ECOG performance status, sarcomatoid histology and bone metastasis allowed for stratification of our patients into 3 distinct groups with median survivals of 18.6, 8.4 and 3.8 months, which were also predictive of survival (p less than 0.05). Conclusions: Risk factors of ECOG performance status, sarcomatoid histology, bone metastasis, history of nephrectomy, recent weight loss and recurrence at the renal bed are predictive of survival in patients treated with biological response modifiers. In addition to previous findings of prognostic factors in renal cancer patients treated with chemotherapy, we identified sarcomatoid histology as an important risk factor in patients treated with biological response modifiers.

Original languageEnglish (US)
Pages (from-to)35-40
Number of pages6
JournalThe Journal of urology
Volume154
Issue number1
DOIs
StatePublished - 1995
Externally publishedYes

Fingerprint

Kidney Neoplasms
Immunologic Factors
Survival
Histology
Neoplasm Metastasis
Bone and Bones
Interferon-beta
Nephrectomy
Interferon-gamma
Weight Loss
Kidney
Recurrence
Renal Cell Carcinoma
Interferon-alpha
Population
Interleukin-2
Multivariate Analysis
Retrospective Studies
Body Weight
Clinical Trials

ASJC Scopus subject areas

  • Urology

Cite this

Prognostic Factors for Survival in Patients with Metastatic Renal Cancer Treated with Biological Response Modifiers. / Mani, Sridhar; Todd, Mary B.; Katz, Karol; Poo, Wen Jen.

In: The Journal of urology, Vol. 154, No. 1, 1995, p. 35-40.

Research output: Contribution to journalArticle

@article{2c8def4a01004834bd50563a2a1a8d38,
title = "Prognostic Factors for Survival in Patients with Metastatic Renal Cancer Treated with Biological Response Modifiers",
abstract = "Purpose: Clinical characteristics prognostic of survival in patients with metastatic renal cell carcinoma treated with biological response modifiers are poorly understood. Understanding these prognostic features may help with better stratification of patients in clinical trials and define further appropriate treatment for each prognostic subgroup. Materials and Methods: A retrospective study of 84 patients with recurrent or metastatic renal cancer was conducted to identify prognostic factors for survival in patients who received biological response modifiers (alpha-interferon, beta-interferon, gamma-interferon and interleukin-2). Results: Univariate analysis identified Eastern Cooperative Oncology Group (ECOG) performance status (1 versus 0, p less than 0.001), bone metastasis (p = 0.008), recent weight loss (greater than 10 percent of total body weight versus no loss, p = 0.028), history of nephrectomy (no versus yes, p = 0.025), recurrence at the renal bed (p = 0.043) and sarcomatoid histology (yes versus no, p less than 0.001) as important prognostic indicators. Multivariate analysis of prognostic factors in this patient population indicated that ECOG performance status, sarcomatoid histology and bone metastasis were most significant, while other factors were less significant (p greater than 0.05) after adjusting for ECOG performance status and sarcomatoid histology. Based on the total positive number of 5 risk factors defined previously the study population separates into 3 risk groups, with a median survival from the low to high risk groups of 14.4, 10.9 and 1.3 months, respectively. Prognostic scores based only on ECOG performance status, sarcomatoid histology and bone metastasis allowed for stratification of our patients into 3 distinct groups with median survivals of 18.6, 8.4 and 3.8 months, which were also predictive of survival (p less than 0.05). Conclusions: Risk factors of ECOG performance status, sarcomatoid histology, bone metastasis, history of nephrectomy, recent weight loss and recurrence at the renal bed are predictive of survival in patients treated with biological response modifiers. In addition to previous findings of prognostic factors in renal cancer patients treated with chemotherapy, we identified sarcomatoid histology as an important risk factor in patients treated with biological response modifiers.",
author = "Sridhar Mani and Todd, {Mary B.} and Karol Katz and Poo, {Wen Jen}",
year = "1995",
doi = "10.1016/S0022-5347(01)67218-5",
language = "English (US)",
volume = "154",
pages = "35--40",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Prognostic Factors for Survival in Patients with Metastatic Renal Cancer Treated with Biological Response Modifiers

AU - Mani, Sridhar

AU - Todd, Mary B.

AU - Katz, Karol

AU - Poo, Wen Jen

PY - 1995

Y1 - 1995

N2 - Purpose: Clinical characteristics prognostic of survival in patients with metastatic renal cell carcinoma treated with biological response modifiers are poorly understood. Understanding these prognostic features may help with better stratification of patients in clinical trials and define further appropriate treatment for each prognostic subgroup. Materials and Methods: A retrospective study of 84 patients with recurrent or metastatic renal cancer was conducted to identify prognostic factors for survival in patients who received biological response modifiers (alpha-interferon, beta-interferon, gamma-interferon and interleukin-2). Results: Univariate analysis identified Eastern Cooperative Oncology Group (ECOG) performance status (1 versus 0, p less than 0.001), bone metastasis (p = 0.008), recent weight loss (greater than 10 percent of total body weight versus no loss, p = 0.028), history of nephrectomy (no versus yes, p = 0.025), recurrence at the renal bed (p = 0.043) and sarcomatoid histology (yes versus no, p less than 0.001) as important prognostic indicators. Multivariate analysis of prognostic factors in this patient population indicated that ECOG performance status, sarcomatoid histology and bone metastasis were most significant, while other factors were less significant (p greater than 0.05) after adjusting for ECOG performance status and sarcomatoid histology. Based on the total positive number of 5 risk factors defined previously the study population separates into 3 risk groups, with a median survival from the low to high risk groups of 14.4, 10.9 and 1.3 months, respectively. Prognostic scores based only on ECOG performance status, sarcomatoid histology and bone metastasis allowed for stratification of our patients into 3 distinct groups with median survivals of 18.6, 8.4 and 3.8 months, which were also predictive of survival (p less than 0.05). Conclusions: Risk factors of ECOG performance status, sarcomatoid histology, bone metastasis, history of nephrectomy, recent weight loss and recurrence at the renal bed are predictive of survival in patients treated with biological response modifiers. In addition to previous findings of prognostic factors in renal cancer patients treated with chemotherapy, we identified sarcomatoid histology as an important risk factor in patients treated with biological response modifiers.

AB - Purpose: Clinical characteristics prognostic of survival in patients with metastatic renal cell carcinoma treated with biological response modifiers are poorly understood. Understanding these prognostic features may help with better stratification of patients in clinical trials and define further appropriate treatment for each prognostic subgroup. Materials and Methods: A retrospective study of 84 patients with recurrent or metastatic renal cancer was conducted to identify prognostic factors for survival in patients who received biological response modifiers (alpha-interferon, beta-interferon, gamma-interferon and interleukin-2). Results: Univariate analysis identified Eastern Cooperative Oncology Group (ECOG) performance status (1 versus 0, p less than 0.001), bone metastasis (p = 0.008), recent weight loss (greater than 10 percent of total body weight versus no loss, p = 0.028), history of nephrectomy (no versus yes, p = 0.025), recurrence at the renal bed (p = 0.043) and sarcomatoid histology (yes versus no, p less than 0.001) as important prognostic indicators. Multivariate analysis of prognostic factors in this patient population indicated that ECOG performance status, sarcomatoid histology and bone metastasis were most significant, while other factors were less significant (p greater than 0.05) after adjusting for ECOG performance status and sarcomatoid histology. Based on the total positive number of 5 risk factors defined previously the study population separates into 3 risk groups, with a median survival from the low to high risk groups of 14.4, 10.9 and 1.3 months, respectively. Prognostic scores based only on ECOG performance status, sarcomatoid histology and bone metastasis allowed for stratification of our patients into 3 distinct groups with median survivals of 18.6, 8.4 and 3.8 months, which were also predictive of survival (p less than 0.05). Conclusions: Risk factors of ECOG performance status, sarcomatoid histology, bone metastasis, history of nephrectomy, recent weight loss and recurrence at the renal bed are predictive of survival in patients treated with biological response modifiers. In addition to previous findings of prognostic factors in renal cancer patients treated with chemotherapy, we identified sarcomatoid histology as an important risk factor in patients treated with biological response modifiers.

UR - http://www.scopus.com/inward/record.url?scp=0029026384&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029026384&partnerID=8YFLogxK

U2 - 10.1016/S0022-5347(01)67218-5

DO - 10.1016/S0022-5347(01)67218-5

M3 - Article

C2 - 7539867

AN - SCOPUS:0029026384

VL - 154

SP - 35

EP - 40

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 1

ER -